IRF4 and neoplasm: Since Tax expression is a strong selective disadvantage during lymphomagenesis and is typically silenced, ATLL cells in the context of tumor immunity may be more sensitive to IRF4-targeted therapies than the same cells cultured ex vivo or as xenografts in immunodeficient mouse models.